Menu

Search

Elixir Medical – International
Elixir Medical – United States
Elixir Medical Corporation

Close Menu

International

January 27, 2021

ELIXIR MEDICAL ANNOUNCES OUTSTANDING 24-MONTH DATA FOR DYNAMX CORONARY BIOADAPTOR SYSTEM, DEMONSTRATING STRONG SAFETY WITH NO TARGET LESION REVASCULARIZATION, MYOCARDIAL INFARCTION OR THROMBOSIS THROUGH 24 MONTHS

rtee 2021, International, Press Release

Successful DynamX Bioadaptor Live Case Presented at Singapore Live

January 13, 2021

ELIXIR MEDICAL ANNOUNCES FIRST PATIENT TREATED IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM

rtee 2021, International, Press Release

International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents

July 28, 2020

Associate Director/Director Clinical Science

elixirmedical Careers, International

The Associate Director/Director Clinical Scientist provides scientific expertise throughout the development and implementation of clinical evaluations, risk management and /or clinical studies.

June 25, 2020

Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive Remodeling of the Artery

elixirmedical 2020, International, Press Release

May 14, 2019

Elixir Medical to Present 9 and 12-Month Clinical and Imaging Data for the DynamX Bioadaptor, Showcasing the Next Frontier Beyond Stenting at EuroPCR 2019

elixirmedical 2019, International, Press Release

October 31, 2017

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery

elixirmedical 2017, International, Press Release

May 17, 2017

Elixir Medical Corporation Announces Outstanding 5-Year Clinical Data for CE Mark-Approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System

elixirmedical 2017, International, Press Release

May 15, 2017

Elixir Medical to Release Five-Year DESolve Nx Trial Data, Showcase Next-Generation Coronary and SFA Bioresorbable Scaffold Systems at EuroPCR 2017

elixirmedical 2017, International, Press Release

November 1, 2016

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System

elixirmedical 2016, International, Press Release

October 31, 2016

Successful Live Case Demonstration of Elixir Medical’s Fully Bioresorbable DESolve NXT Plus Novolimus Eluting Coronary Scaffold System at TCT

elixirmedical 2016, International, Press Release

Recent Posts

ELIXIR MEDICAL ANNOUNCES OUTSTANDING 24-MONTH DATA FOR DYNAMX CORONARY BIOADAPTOR SYSTEM, DEMONSTRATING STRONG SAFETY WITH NO TARGET LESION REVASCULARIZATION, MYOCARDIAL INFARCTION OR THROMBOSIS THROUGH 24 MONTHS
ELIXIR MEDICAL ANNOUNCES OUTSTANDING 24-MONTH DATA FOR DYNAMX CORONARY BIOADAPTOR SYSTEM, DEMONSTRATING STRONG SAFETY WITH NO TARGET LESION REVASCULARIZATION, MYOCARDIAL INFARCTION OR THROMBOSIS THROUGH 24 MONTHS
ELIXIR MEDICAL ANNOUNCES FIRST PATIENT TREATED IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
ELIXIR MEDICAL ANNOUNCES FIRST PATIENT TREATED IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive Remodeling of the Artery

© Elixir Medical 2021

Powered by WordPress • Themify WordPress Themes

In order to provide you with an optimal website experience, we use cookies. By clicking "Accept" you agree to the use of cookies. Further information can be found in our privacy policy.ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.